Liver Cancer News and Research

RSS

Liver cancer is more common in older people. Over half of people newly diagnosed with liver cancer are age 65 and over. Liver cancer is more common in men than in women. Liver cancer rates are highest among Asians and Pacific Islanders, most likely because of higher prevalence of viral Hepatitis infection. Liver cancer rates are lower among whites than Blacks or Asians and Pacific Islanders. At this time, we do not know exactly what causes cancer of the liver. There are several different types of liver cancer. The most common type is associated with long-term excessive alcoholic beverage use, scarring of the liver (cirrhosis), and Hepatitis B virus or Hepatitis C virus infection. Long-term use of anabolic steroids can also increase the risk of getting liver cancer. Smoking is also believed to increase the risk of getting liver cancer.

Men should see a doctor and be proactive about their health, say UAB experts

Experts at the University of Alabama at Birmingham (UAB) say a man's tendency to wait until the onset of sickness to see his doctor is a major detriment to health because key screenings are missed.

1 Dec 2012

Diabetes education critical for uncontrolled high blood sugar people with cancer

When people with Type 2 diabetes are diagnosed with cancer -- a disease for which they are at higher risk -- they ignore their diabetes care to focus on cancer treatment, according to new Northwestern Medicine- research. But uncontrolled high blood sugar is more likely to kill them and impairs their immune system's ability to fight cancer.

30 Nov 2012

GW researcher gets NCI grant to study behavior of parasitic worm in bile duct cancer

Paul Brindley, Ph.D., professor of microbiology, immunology, and tropical medicine at the George Washington University School of Medicine and Health Sciences, was the recipient of a $1.7 million grant from the National Cancer Institute to study the behavior of a parasitic worm, rampant in Southeast Asia, known to cause infections that contribute to liver cancer.

16 Nov 2012

Abbott releases details on phase 3 hepatitis C registrational program

Abbott today released details on its phase 3 hepatitis C registrational program following promising results from its phase 2b clinical trial, known as Aviator, presented at the Annual Meeting of the American Association for the Study of Liver Disease (AASLD) in Boston.

13 Nov 2012

FDA grants Albireo's A4250 orphan-drug designation for treatment of PFIC and PBC

Albireo AB, a biopharmaceutical company specializing in gastroenterology, today announced that A4250 (an inhibitor of the ileal bile acid transporter, IBAT/ASBT) has been granted orphan-drug designation by the U.S Food and Drug Administration for the treatment of Progressive Familial Intrahepatic Cholestasis (PFIC) and Primary Biliary Cirrhosis (PBC).

8 Nov 2012

Scientists show how sorafenib can be dangerous to the heart

Scientists for the first time have evidence showing how a widely used type of "targeted" cancer drug can be dangerous to the heart.

7 Nov 2012

SCYNEXIS announces results from SCY-635 Phase 2a study on HCV

SCYNEXIS, Inc. today announced that the results of a Phase 2a study of lead candidate SCY-635 for the treatment of the hepatitis C virus (HCV) will be the subject of an oral presentation at the 63rd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), taking place from November 9-13 in Boston, Massachusetts.

7 Nov 2012

UC Irvine, Cal State Fullerton partner to help reduce cancer disparities in Orange County

Researchers from UC Irvine's Chao Family Comprehensive Cancer Center and California State University, Fullerton's Health Promotion Research Institute have formed a partnership to help reduce cancer disparities in Orange County.

2 Nov 2012

Nitisinone treatment effectively prevents tyrosinemia in children

A consortium of Quebec researchers coordinated by the Medical Genetics Service of the Sainte-Justine UHC has just published the findings of a 25-year study on the treatment of tyrosinemia, a life-threatening liver disease of genetic origin, which is screened at birth in the province of Quebec, where it is much more frequent than anywhere else in the world.

1 Nov 2012

BioCryst announces withdrawal of BCX5191 IND following discussion with FDA

BioCryst Pharmaceuticals, Inc. announced the withdrawal of its Investigational New Drug application (IND) for the antiviral nucleoside, BCX5191, following a discussion with the U.S. Food and Drug Administration (FDA).

31 Oct 2012

Chemists' innovation may be a better model for disease diagnostic kits

When someone develops liver cancer, the disease introduces a very subtle difference to their bloodstream, increasing the concentration of a particular molecule by just 10 parts per billion.

29 Oct 2012

Antiviral therapy cuts progression to cancer in hepatitis

Antiviral therapy may prevent the most common form of liver cancer developing among patients who have hepatitis C-related fibrosis or cirrhosis, report researchers.

25 Oct 2012

BioLineRx completes pre-clinical development of BL-8020 for HCV

BioLineRx, a biopharmaceutical development company, announced today that it has successfully completed the pre-clinical development of BL-8020, an orally available, interferon-free treatment for the Hepatitis C virus (HCV), and plans to commence a Phase I/II safety and efficacy study for BL-8020 in Europe during the first quarter of 2013.

17 Oct 2012

Statins could be first preventive treatment for liver cancer

Statins may reduce the risk for hepatocellular carcinoma, show the results of a meta-analysis.

15 Oct 2012

Scientists look to use natural killer cells to target common form of liver cancer

Scientists at the University of Southampton are to investigate the best way to use natural killer cells (NK) to target the most common form of liver cancer. NK cells are able to directly kill cancer in the body and stimulate other cells in the immune system to help attack cancer.

14 Oct 2012

Researchers decipher how AP-1 gene regulator controls survival of liver tumor-initiating cells

Researchers headed by Erwin Wagner, the Director of the BBVA Foundation-CNIO Cancer Cell Biology Programme at the Spanish National Cancer Research Centre (CNIO), have deciphered how a stress-inducible gene regulator, AP-1, controls the survival of liver tumor-initiating cells. These results, published in the online edition of Nature Cell Biology, could provide new preventive strategies and identify potentially targetable molecules to prevent liver cancer.

8 Oct 2012

Provectus amends and expands protocol for PV-10 Phase 1 hepatocellular carcinoma study

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announced that it has amended and expanded the scope of the protocol PV-10-LC-01, "A Phase 1 Study to Assess the Safety, Tolerability and Pharmacokinetics of PV-10 Chemoablation of Cancer Metastatic to the Liver or Hepatocellular Carcinoma not Amenable to Resection or Transplant."

28 Sep 2012

LIFR protein suppresses local invasion and metastasis of breast cancer cells

A receptor protein suppresses local invasion and metastasis of breast cancer cells, the most lethal aspect of the disease, according to a research team headed by scientists from The University of Texas MD Anderson Cancer Center.

25 Sep 2012

BioAlliance, Vestiq enter licensing agreement to commercialize Oravig in the US

BioAlliance Pharma SA, an innovative Company dedicated to the development of orphan oncology products and to supportive care products, announces the execution of the licensing agreement with Vestiq Pharmaceuticals to commercialize Oravig in the United States for the treatment of oropharyngeal candidiasis in adults.

24 Sep 2012

RRM2 may be a facilitating factor in colorectal cancer and UV-induced DNA damage repair

Colorectal cancer (CRC) is the leading cause of cancer-related death worldwide. In addition, the incidence and mortality rates of colorectal cancer are on the rise. Recently, metabolic genes have received increasing and specific attention due to their potential role in carcinogenesis.

20 Sep 2012